| Literature DB >> 20223767 |
Isin Ertongur1, Nils-Sebastian Tomi, André Kutzera, Sabine Fischer-Burkart, Berit Jungnickel.
Abstract
In contrast to lower eukaryotes, most vertebrate cells are characterized by a moderate efficiency of homologous recombination (HR) and limited feasibility of targeted genetic modifications. As a notable exception, the chicken DT40 B cell line is distinguished by efficient homology-mediated repair of DNA lesions during Ig gene conversion, and also shows exceptionally high gene-targeting efficiencies. The molecular basis of these phenomena is elusive. Here we show that the activity levels of Ubc13, the E2 enzyme responsible for non-canonical K63-linked polyubiquitination, are critical for high efficiency of Ig gene conversion and gene targeting in DT40. Ubc13(+/-) cells show substantially lower homology-mediated repair, yet do not display changes in somatic hypermutation, overall DNA repair or cell proliferation. Our results suggest that modulation of the activity of K63-linked polyubiquitination may be used to customize HR efficiencies in vertebrate cells.Entities:
Mesh:
Substances:
Year: 2010 PMID: 20223767 PMCID: PMC2919702 DOI: 10.1093/nar/gkq154
Source DB: PubMed Journal: Nucleic Acids Res ISSN: 0305-1048 Impact factor: 16.971
Sequences of oligonucleotides used in this study
| Name | Sequence |
|---|---|
| 13Ub1 | 5′-gggctcgagtccagcctggccttggctgcttcca-3′ |
| 13Ub2 | 5′-gggggatcccaaactgtttaacgtaagcactctg-3′ |
| 13Ub3 | 5′-gggggatccgaataaaagcccagacatcttcagt-3′ |
| 13Ub4 | 5′-gggactagtaccttcagacacagcactactaccg-3′ |
| 13Ub8 | 5′-gaagctagcgccaccatggccgggctgcccc-3′ |
| 13Ub9 | 5′-gggagatctgtcttggcagaacaggagaagtgat-3′ |
| 13Ub101 | 5′-tagaatcatacagtggtttgggttgga-3′ |
| Pu4 | 5′-cagcgcccgaccgaaaggagcgca-3′ |
| Bs1 | 5′-cgattgaagaactcattccactcaaatatataccc-3′ |
| 13Ub201 | 5′-gtgtaagaggacaagcaagatac-3′ |
| 13Ub202 | 5′-agttgggctaaatgaccttcg-3′ |
Figure 1.Targeting and reconstitution of Ubc13. (A) Targeting strategy for Ubc13 in DT40 cells. Boxes indicate exons, shaded areas correspond to coding sequences. Restriction sites and fragment sizes for southern analyses are shown. Bold lines correspond to homologous arms of the targeting vector. (B) Southern Blot analysis of the DT40 clones used for analysis of Ig GC. 2 independent heterozygous (Ubc13+/−) and reconstituted clones (Ubc13+/−R) were employed. (C) Western Blot for Ubc13 and AID expression in the clones analysed in (B).
Figure 2.Ubc13 dosage affects Ig GC. (A) FACS analysis for sIg expression of representative single cell clones of the cells with the indicated genotypes. Percentage of sIg+ cells are given. (B) Percentage of sIg+ cells in individual single-cell clones of the indicated genotypes. Total numbers of clones analysed are given below the genotype. Bars represent mean values. Brackets and stars mark statistically significant differences (Student’s t-test). P-values for Cre1 compared to the reconstituted clones were 0.20367 and 0.07022, respectively. (C) Sequence analysis of the rearranged light chain gene in representative clones of the cells analysed in (B). The shaded letter marks the original frameshift mutation in DT40Cre1 cells. Brackets mark deletions. The frequency of the events shown among a total of 24 sequences each, as well as the most likely pseudogene with which recombination occurred, are indicated on the right side.
Figure 3.Effects of Ubc13 dosage on SHM. (A) Percentage of sIg− cells in individual single-cell clones of the indicated genotypes. The total number of clones analysed is given below the respective genotype. P-values for ψV- compared to ψV- Ubc13+/− and ψV- Ubc13+/−R were 0.56002 and 0.77197, respectively. (B) Sequence analysis of the rearranged light chain gene in the clones analysed in (A). The relative fraction of sequences with the indicated number of mutations per sequence is given. Total numbers of sequences are shown in the insets, and the mutation frequency is given below the genotype.
Targeting efficiencies in WT versus Ubc13+/− clones
| Targeted loci | Rad18 | RDM1 |
|---|---|---|
| DT40 Cre1 | 18/45 (40%) | 29/100 (29%) |
| Ubc13+/− clone 1 | 5/45 (11%) | 18/100 (18%) |
| Ubc13+/− clone 2 | 3/45 (7%) | 16/100 (16%) |